Trial · NCT07890766
Management of Breast Fibroadenoma: Comparing Observation, Microwave Ablation, and Surgical Excision
NCT07890766, Not applicable, Not yet recruiting, Sohag University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Management of Breast Fibroadenoma: Comparing Observation, Microwave Ablation, and Surgical Excision. Trials, record NCT07890766. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07890766
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Management of Breast Fibroadenoma: Comparing Observation, Microwave Ablation, and Surgical Excision
- NCT number
- NCT07890766
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Sohag University
- Conditions
- Fibroadenoma, Breast Fibroadenoma, Benign Breast Disease
- Interventions
- Ultrasound-guided percutaneous microwave ablation, Conventional open surgical excision
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Treatment Success Rate | 6 months post-procedure | In the microwave ablation group, treatment success is defined as technically successful complete ablation with progressive reduction in lesion volume on ultrasound, absence of vascularity or tumor regrowth, and no need for secondary intervention. In the surgical excision group, it is defined as histologically confirmed complete lesion removal with no residual or recurrent mass and no reoperation. In the conservative group, success is defined as stability without symptom progression or crossover to intervention. |
| Secondary | Postoperative Pain Score | At 24 hours, 1 week, and 1 month post-procedure | Assessed using the Visual Analogue Scale (VAS) ranging from 0 (no pain) to 10 (worst possible pain). |
| Secondary | Lesion Volume Reduction Ratio | At 1, 3, 6, and 12 months post-procedure | Calculated using ultrasound three-dimensional diameter measurements to assess the percentage of volume reduction in the microwave ablation group compared to baseline pre-procedure volume. |
| Secondary | Cosmetic Outcome and Patient Satisfaction | 6 and 12 months post-procedure | Evaluated based on scar visibility, breast contour deformity, symmetry, and overall patient perception, graded as excellent, good, fair, or poor. |
| Secondary | Operative Duration | Intraoperatively (during the procedure) | Measured in minutes from the beginning of the intervention (antenna insertion or incision) to the completion of hemostasis and wound dressing. |
| Secondary | Post-procedure Complications Rate | Up to 12 months post-procedure | Incidence of any intraoperative or postoperative adverse events, including bleeding, hematoma, skin burn, wound infection, seroma, or persistent pain. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07890766
GET https://conductscience.org/api/trials/v1/NCT07890766/registered